-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Aadi Bioscience, Inc. (NASDAQ:AADI) Position Raised by Point72 Asset Management L.P.
Aadi Bioscience, Inc. (NASDAQ:AADI) Position Raised by Point72 Asset Management L.P.
Point72 Asset Management L.P. increased its position in shares of Aadi Bioscience, Inc. (NASDAQ:AADI – Get Rating) by 156.2% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 542,044 shares of the company's stock after purchasing an additional 330,513 shares during the period. Point72 Asset Management L.P. owned 2.59% of Aadi Bioscience worth $6,678,000 at the end of the most recent quarter.
Several other hedge funds have also recently added to or reduced their stakes in AADI. Qube Research & Technologies Ltd acquired a new position in Aadi Bioscience in the first quarter worth approximately $294,000. Decheng Capital Management III Cayman LLC acquired a new position in Aadi Bioscience in the first quarter worth approximately $8,932,000. Renaissance Technologies LLC grew its position in Aadi Bioscience by 8.6% in the first quarter. Renaissance Technologies LLC now owns 139,522 shares of the company's stock worth $2,368,000 after buying an additional 11,000 shares during the last quarter. UBS Group AG grew its position in Aadi Bioscience by 135.3% in the first quarter. UBS Group AG now owns 56,684 shares of the company's stock worth $961,000 after buying an additional 32,590 shares during the last quarter. Finally, Eversept Partners LP acquired a new position in Aadi Bioscience in the first quarter worth approximately $2,559,000. Institutional investors and hedge funds own 63.00% of the company's stock.
Get Aadi Bioscience alerts:Aadi Bioscience Stock Performance
AADI stock opened at $13.26 on Friday. The firm has a 50 day simple moving average of $13.18 and a 200 day simple moving average of $13.32. Aadi Bioscience, Inc. has a 52 week low of $11.00 and a 52 week high of $26.60. The stock has a market cap of $323.54 million, a P/E ratio of -4.45 and a beta of 1.28.
Aadi Bioscience (NASDAQ:AADI – Get Rating) last released its earnings results on Wednesday, November 9th. The company reported ($0.68) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.75) by $0.07. Aadi Bioscience had a negative net margin of 569.57% and a negative return on equity of 44.28%. The company had revenue of $4.25 million during the quarter, compared to the consensus estimate of $3.60 million. Sell-side analysts predict that Aadi Bioscience, Inc. will post -2.86 EPS for the current year.Wall Street Analyst Weigh In
Separately, LADENBURG THALM/SH SH cut their target price on shares of Aadi Bioscience to $47.00 in a research note on Tuesday, November 15th.
About Aadi Bioscience
(Get Rating)
Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway.
Featured Stories
- Get a free copy of the StockNews.com research report on Aadi Bioscience (AADI)
- MarketBeat: Week in Review 12/05 – 12/09
- There Is Fundamental Value In Broadcom, And It Yields 3.35%
- Costco vs Amazon: an end of the year showdown
- Discount Retailers Could Make Good Bargain Stocks
- Can Pfizer, Johnson & Johnson Continue Outperforming the Index?
Receive News & Ratings for Aadi Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aadi Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
Point72 Asset Management L.P. increased its position in shares of Aadi Bioscience, Inc. (NASDAQ:AADI – Get Rating) by 156.2% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 542,044 shares of the company's stock after purchasing an additional 330,513 shares during the period. Point72 Asset Management L.P. owned 2.59% of Aadi Bioscience worth $6,678,000 at the end of the most recent quarter.
根据Aadi Bioscience，Inc.(纳斯达克：AADI-GET评级)在提交给美国证券交易委员会(美国证券交易委员会)的最新Form 13F文件中显示，Point72 Asset Management L.P.在第二季度将其在该公司股票的持仓增加了156.2。该机构投资者持有542,044股该公司股票，在此期间又购买了330,513股。截至最近一个季度末，Point72 Asset Management L.P.拥有Aadi Bioscience 2.59%的股份，价值667.8万美元。
Several other hedge funds have also recently added to or reduced their stakes in AADI. Qube Research & Technologies Ltd acquired a new position in Aadi Bioscience in the first quarter worth approximately $294,000. Decheng Capital Management III Cayman LLC acquired a new position in Aadi Bioscience in the first quarter worth approximately $8,932,000. Renaissance Technologies LLC grew its position in Aadi Bioscience by 8.6% in the first quarter. Renaissance Technologies LLC now owns 139,522 shares of the company's stock worth $2,368,000 after buying an additional 11,000 shares during the last quarter. UBS Group AG grew its position in Aadi Bioscience by 135.3% in the first quarter. UBS Group AG now owns 56,684 shares of the company's stock worth $961,000 after buying an additional 32,590 shares during the last quarter. Finally, Eversept Partners LP acquired a new position in Aadi Bioscience in the first quarter worth approximately $2,559,000. Institutional investors and hedge funds own 63.00% of the company's stock.
其他几家对冲基金最近也增持或减持了Aadi的股份。Qube Research&Technologies Ltd在第一季度收购了Aadi Bioscience的一个新头寸，价值约29.4万美元。德成资本管理III开曼有限责任公司在第一季度收购了Aadi Bioscience的一个新头寸，价值约893.2万美元。复兴科技有限公司在第一季度将其在Aadi Bioscience的头寸增加了8.6%。复兴科技有限责任公司现在拥有139,522股该公司股票，价值2,368,000美元，在上个季度又购买了11,000股。今年第一季度，瑞银集团在Aadi Bioscience的持仓增加了135.3%。瑞银集团(UBS Group AG)目前持有56,684股该公司股票，价值961,000美元，上一季度又购买了32,590股。最后，Eversept Partners LP在第一季度收购了Aadi Bioscience的一个新头寸，价值约2,559,000美元。机构投资者和对冲基金持有该公司63.00%的股票。
Aadi Bioscience Stock Performance
Aadi Bioscience股票表现
AADI stock opened at $13.26 on Friday. The firm has a 50 day simple moving average of $13.18 and a 200 day simple moving average of $13.32. Aadi Bioscience, Inc. has a 52 week low of $11.00 and a 52 week high of $26.60. The stock has a market cap of $323.54 million, a P/E ratio of -4.45 and a beta of 1.28.
上周五，Aadi股价开盘报13.26美元。该公司的50日简单移动均线切入位在13.18美元，200日简单移动均线切入位在13.32美元。Aadi Bioscience，Inc.的52周低点为11.00美元，52周高位为26.60美元。该股市值为3.2354亿美元，市盈率为-4.45，贝塔系数为1.28。
Wall Street Analyst Weigh In
华尔街分析师也加入进来
Separately, LADENBURG THALM/SH SH cut their target price on shares of Aadi Bioscience to $47.00 in a research note on Tuesday, November 15th.
另外，拉登堡THALM/SH SH在11月15日星期二的一份研究报告中将Aadi Bioscience的目标价下调至47.00美元。
About Aadi Bioscience
关于Aadi生物科学
(Get Rating)
(获取评级)
Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway.
Aadi Bioscience，Inc.是一家临床阶段的生物制药公司，致力于开发和商业化mTOR途径基因改变的基因定义癌症的精确疗法。它的主要候选药物FYARRO是一种与白蛋白结合的西罗莫司。AADI正在评估已知mTOR途径激活的癌症的FYARRO，包括针对激活mTOR途径的特定基因组改变的肿瘤不可知适应症。
Featured Stories
专题报道
- Get a free copy of the StockNews.com research report on Aadi Bioscience (AADI)
- MarketBeat: Week in Review 12/05 – 12/09
- There Is Fundamental Value In Broadcom, And It Yields 3.35%
- Costco vs Amazon: an end of the year showdown
- Discount Retailers Could Make Good Bargain Stocks
- Can Pfizer, Johnson & Johnson Continue Outperforming the Index?
- 免费获取StockNews.com关于Aadi生物科学的研究报告(AADI)
- MarketBeat：回顾一周12/05-12/09
- 博通有基本面价值，收益率为3.35%
- 好市多VS亚马逊：年底摊牌
- 折扣零售商可以做好的便宜货
- 辉瑞、强生能否继续跑赢该指数？
Receive News & Ratings for Aadi Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aadi Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
获得《Aadi生物科学日报》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Aadi Bioscience和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧